| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 37 | 2019 | 4557 | 1.700 |
Why?
|
| Colorectal Neoplasms | 23 | 2018 | 3578 | 1.370 |
Why?
|
| Tomography, X-Ray Computed | 32 | 2020 | 7551 | 1.150 |
Why?
|
| Hepatectomy | 16 | 2018 | 1011 | 0.810 |
Why?
|
| Bevacizumab | 10 | 2018 | 938 | 0.640 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2016 | 1248 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 6 | 2011 | 4367 | 0.510 |
Why?
|
| Liver Diseases | 3 | 2015 | 574 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2019 | 10035 | 0.460 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2013 | 167 | 0.400 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.340 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 1226 | 0.340 |
Why?
|
| Catheter Ablation | 6 | 2017 | 620 | 0.330 |
Why?
|
| Camptothecin | 9 | 2012 | 517 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2013 | 3251 | 0.310 |
Why?
|
| Bile Duct Neoplasms | 4 | 2016 | 493 | 0.290 |
Why?
|
| Organoplatinum Compounds | 7 | 2018 | 702 | 0.290 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2016 | 334 | 0.270 |
Why?
|
| Portal Vein | 4 | 2013 | 355 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2018 | 15862 | 0.260 |
Why?
|
| Middle Aged | 58 | 2019 | 86204 | 0.260 |
Why?
|
| Image Enhancement | 3 | 2017 | 561 | 0.260 |
Why?
|
| Abscess | 2 | 1996 | 177 | 0.240 |
Why?
|
| Aged | 45 | 2019 | 70117 | 0.230 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 550 | 0.230 |
Why?
|
| Adult | 49 | 2019 | 77950 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 2027 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 9 | 2020 | 5061 | 0.220 |
Why?
|
| Contrast Media | 9 | 2017 | 1472 | 0.210 |
Why?
|
| Female | 65 | 2020 | 141928 | 0.210 |
Why?
|
| Male | 52 | 2020 | 123000 | 0.210 |
Why?
|
| Aged, 80 and over | 22 | 2019 | 29902 | 0.200 |
Why?
|
| Humans | 85 | 2020 | 261506 | 0.200 |
Why?
|
| Abdomen | 2 | 2020 | 332 | 0.200 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 4744 | 0.200 |
Why?
|
| Sesquiterpenes | 2 | 1998 | 68 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 384 | 0.190 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2020 | 54 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2016 | 7702 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2016 | 3890 | 0.180 |
Why?
|
| Gallbladder Neoplasms | 2 | 2016 | 245 | 0.170 |
Why?
|
| Retrospective Studies | 21 | 2020 | 37905 | 0.170 |
Why?
|
| Cellulitis | 2 | 1996 | 72 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2001 | 1833 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 1656 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1998 | 726 | 0.150 |
Why?
|
| Carcinoma | 3 | 2016 | 2578 | 0.150 |
Why?
|
| Laparoscopy | 2 | 2016 | 1225 | 0.150 |
Why?
|
| Preoperative Care | 3 | 2013 | 1529 | 0.150 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 88 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2017 | 1648 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 193 | 0.140 |
Why?
|
| Treatment Outcome | 23 | 2019 | 32848 | 0.140 |
Why?
|
| Survival Rate | 13 | 2019 | 12221 | 0.140 |
Why?
|
| Feedback | 1 | 2017 | 198 | 0.140 |
Why?
|
| Embolization, Therapeutic | 2 | 2013 | 551 | 0.140 |
Why?
|
| Diagnostic Imaging | 4 | 2010 | 1162 | 0.140 |
Why?
|
| Neoplasm Staging | 11 | 2016 | 13658 | 0.130 |
Why?
|
| Hodgkin Disease | 2 | 2004 | 1429 | 0.130 |
Why?
|
| Klatskin Tumor | 1 | 2016 | 29 | 0.130 |
Why?
|
| Connective Tissue | 1 | 1995 | 43 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 1547 | 0.130 |
Why?
|
| Pancreas | 4 | 2001 | 718 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2003 | 852 | 0.130 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2003 | 153 | 0.130 |
Why?
|
| Vascular Neoplasms | 1 | 1996 | 114 | 0.130 |
Why?
|
| Soft Tissue Infections | 1 | 1996 | 102 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2006 | 1039 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 1999 | 493 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2018 | 846 | 0.120 |
Why?
|
| Topotecan | 4 | 2014 | 239 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2001 | 5437 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2014 | 2819 | 0.110 |
Why?
|
| Lipase | 1 | 2013 | 112 | 0.110 |
Why?
|
| Paclitaxel | 5 | 2014 | 1996 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 336 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 585 | 0.100 |
Why?
|
| Combined Modality Therapy | 9 | 2016 | 8865 | 0.100 |
Why?
|
| Taxoids | 3 | 2007 | 967 | 0.100 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 2173 | 0.100 |
Why?
|
| Liver Regeneration | 2 | 2013 | 134 | 0.100 |
Why?
|
| Lung | 2 | 2000 | 3151 | 0.100 |
Why?
|
| Disease-Free Survival | 9 | 2014 | 10001 | 0.100 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 14889 | 0.100 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 1271 | 0.100 |
Why?
|
| Hamartoma | 1 | 1992 | 115 | 0.100 |
Why?
|
| Antineoplastic Agents | 8 | 2011 | 14289 | 0.100 |
Why?
|
| ras Proteins | 1 | 2014 | 770 | 0.090 |
Why?
|
| Postoperative Complications | 4 | 2011 | 5542 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 3 | 2003 | 821 | 0.090 |
Why?
|
| Fluorouracil | 4 | 2018 | 1944 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2010 | 158 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 4971 | 0.090 |
Why?
|
| Ablation Techniques | 1 | 2010 | 148 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 122 | 0.080 |
Why?
|
| Patient Selection | 3 | 2013 | 2055 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 1999 | 2326 | 0.080 |
Why?
|
| Surgical Flaps | 2 | 1995 | 927 | 0.080 |
Why?
|
| Proton Therapy | 1 | 2019 | 1577 | 0.080 |
Why?
|
| Prognosis | 10 | 2018 | 21713 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 895 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 1999 | 3022 | 0.080 |
Why?
|
| Heart Diseases | 1 | 1993 | 732 | 0.070 |
Why?
|
| Liver | 4 | 2018 | 2961 | 0.070 |
Why?
|
| Breast Neoplasms | 6 | 2016 | 15694 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 1997 | 2967 | 0.070 |
Why?
|
| Adenoma | 1 | 2012 | 716 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6207 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2016 | 5178 | 0.070 |
Why?
|
| Esophageal Fistula | 1 | 1986 | 27 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 941 | 0.070 |
Why?
|
| Bronchial Fistula | 1 | 1986 | 37 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2006 | 749 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 1993 | 1411 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2003 | 4638 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 2488 | 0.070 |
Why?
|
| Injections, Intravenous | 3 | 2006 | 573 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 235 | 0.060 |
Why?
|
| Liposomes | 2 | 2004 | 684 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 882 | 0.060 |
Why?
|
| Vena Cava, Inferior | 2 | 2019 | 190 | 0.060 |
Why?
|
| Breast | 1 | 1991 | 1344 | 0.060 |
Why?
|
| Ligaments | 1 | 2004 | 43 | 0.060 |
Why?
|
| Immunotherapy | 1 | 1997 | 3341 | 0.060 |
Why?
|
| Colitis | 1 | 2007 | 340 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2009 | 713 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 101 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2004 | 133 | 0.060 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 5112 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 2004 | 108 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 2594 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 297 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2015 | 276 | 0.060 |
Why?
|
| Leucovorin | 2 | 2018 | 332 | 0.060 |
Why?
|
| Bile Duct Diseases | 1 | 2003 | 45 | 0.060 |
Why?
|
| Radiotherapy | 4 | 2000 | 1824 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2003 | 167 | 0.050 |
Why?
|
| Spleen | 2 | 2018 | 676 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 7789 | 0.050 |
Why?
|
| Western World | 1 | 2002 | 8 | 0.050 |
Why?
|
| Body Surface Area | 1 | 2002 | 42 | 0.050 |
Why?
|
| Lymphangioma, Cystic | 1 | 2001 | 20 | 0.050 |
Why?
|
| Lung Neoplasms | 3 | 2004 | 11538 | 0.050 |
Why?
|
| Prospective Studies | 6 | 2014 | 12873 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 1904 | 0.050 |
Why?
|
| Cyclohexanes | 2 | 1998 | 38 | 0.050 |
Why?
|
| Neutrophils | 1 | 2006 | 835 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4549 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2003 | 176 | 0.050 |
Why?
|
| Radiation Pneumonitis | 2 | 2000 | 301 | 0.050 |
Why?
|
| Organ Size | 2 | 2018 | 690 | 0.050 |
Why?
|
| Infusions, Intravenous | 5 | 2003 | 1382 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2016 | 1216 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2006 | 3472 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2008 | 4938 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 56 | 0.040 |
Why?
|
| Gadolinium DTPA | 2 | 2012 | 172 | 0.040 |
Why?
|
| Bleomycin | 1 | 2000 | 467 | 0.040 |
Why?
|
| Ultrasonography | 2 | 1996 | 1863 | 0.040 |
Why?
|
| Hysterosalpingography | 1 | 1998 | 15 | 0.040 |
Why?
|
| Mammaplasty | 2 | 1997 | 780 | 0.040 |
Why?
|
| Osteocalcin | 1 | 1998 | 87 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1998 | 84 | 0.040 |
Why?
|
| Recurrence | 4 | 2014 | 4758 | 0.040 |
Why?
|
| Neoplasms | 2 | 2019 | 15193 | 0.040 |
Why?
|
| Bone Remodeling | 1 | 1998 | 104 | 0.040 |
Why?
|
| Bone Resorption | 1 | 1998 | 138 | 0.040 |
Why?
|
| Forecasting | 2 | 2002 | 694 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 361 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 226 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 726 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4849 | 0.040 |
Why?
|
| Body Weight | 1 | 2002 | 1293 | 0.040 |
Why?
|
| Cartilage Diseases | 1 | 1997 | 23 | 0.040 |
Why?
|
| Adolescent | 5 | 2019 | 31252 | 0.040 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2016 | 16 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 980 | 0.040 |
Why?
|
| Piperazines | 1 | 2006 | 2101 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2017 | 117 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 543 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2016 | 159 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 447 | 0.040 |
Why?
|
| Cholecystitis | 1 | 2016 | 52 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 6009 | 0.040 |
Why?
|
| Celiac Artery | 1 | 1996 | 40 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2016 | 68 | 0.030 |
Why?
|
| Mesenteric Arteries | 1 | 1996 | 55 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1997 | 557 | 0.030 |
Why?
|
| Palpation | 1 | 1995 | 49 | 0.030 |
Why?
|
| Digestive System | 1 | 1996 | 114 | 0.030 |
Why?
|
| Thorax | 1 | 2016 | 213 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1997 | 315 | 0.030 |
Why?
|
| Mammary Arteries | 1 | 1995 | 64 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 215 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1999 | 935 | 0.030 |
Why?
|
| Urinary Tract | 1 | 1996 | 82 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1998 | 604 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 4988 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 1996 | 240 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2006 | 334 | 0.030 |
Why?
|
| Axilla | 1 | 1997 | 902 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 217 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 272 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 1997 | 246 | 0.030 |
Why?
|
| Mutation | 1 | 2014 | 15179 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 335 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 1997 | 545 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 10331 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1997 | 842 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 4892 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2013 | 162 | 0.030 |
Why?
|
| Calcinosis | 1 | 1997 | 423 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 1996 | 402 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 1183 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2006 | 3518 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 889 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 388 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2013 | 75 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2014 | 9180 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 178 | 0.030 |
Why?
|
| Carcinoma, Lobular | 1 | 2016 | 611 | 0.030 |
Why?
|
| Mastectomy | 2 | 1997 | 1534 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1014 | 0.030 |
Why?
|
| Splenic Vein | 1 | 2012 | 17 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 1382 | 0.030 |
Why?
|
| Time Factors | 4 | 2011 | 12926 | 0.030 |
Why?
|
| Gadolinium | 1 | 2013 | 164 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1742 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 864 | 0.030 |
Why?
|
| Mesenteric Veins | 1 | 2012 | 73 | 0.020 |
Why?
|
| Disease Progression | 2 | 2019 | 6682 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 2 | 2003 | 183 | 0.020 |
Why?
|
| Arm | 1 | 1992 | 147 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 204 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 17523 | 0.020 |
Why?
|
| Consensus | 1 | 2015 | 978 | 0.020 |
Why?
|
| Abdominal Muscles | 1 | 1991 | 68 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 4844 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1819 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2014 | 2054 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 4975 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 2927 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 472 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2013 | 6869 | 0.020 |
Why?
|
| Heart | 1 | 1996 | 1223 | 0.020 |
Why?
|
| Rituximab | 1 | 2014 | 1528 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 490 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| Cisplatin | 2 | 2008 | 2432 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 2370 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1996 | 3981 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2007 | 69 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3203 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 460 | 0.020 |
Why?
|
| Texas | 2 | 2011 | 6311 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2012 | 9244 | 0.020 |
Why?
|
| Filgrastim | 1 | 2006 | 191 | 0.020 |
Why?
|
| Carboplatin | 2 | 2001 | 823 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2006 | 68 | 0.020 |
Why?
|
| Mammography | 1 | 1991 | 1010 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 1290 | 0.020 |
Why?
|
| Incidence | 2 | 2006 | 5673 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 684 | 0.020 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2004 | 6 | 0.020 |
Why?
|
| Length of Stay | 1 | 2011 | 1900 | 0.020 |
Why?
|
| Italy | 1 | 2004 | 236 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2008 | 1021 | 0.010 |
Why?
|
| Receptors, LHRH | 1 | 2003 | 41 | 0.010 |
Why?
|
| Diaphragm | 1 | 2004 | 181 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6100 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 120 | 0.010 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 285 | 0.010 |
Why?
|
| Duodenum | 1 | 2004 | 149 | 0.010 |
Why?
|
| Young Adult | 2 | 2014 | 21445 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 16273 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 615 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 1390 | 0.010 |
Why?
|
| Radiology | 1 | 2007 | 434 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 1202 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 1665 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2002 | 154 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 4654 | 0.010 |
Why?
|
| Benzamides | 1 | 2006 | 1832 | 0.010 |
Why?
|
| Platinum Compounds | 1 | 2000 | 131 | 0.010 |
Why?
|
| Bile Ducts | 1 | 2000 | 113 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2001 | 305 | 0.010 |
Why?
|
| Iohexol | 1 | 1998 | 58 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2001 | 500 | 0.010 |
Why?
|
| Myometrium | 1 | 1998 | 79 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 1546 | 0.010 |
Why?
|
| Premenopause | 1 | 1998 | 131 | 0.010 |
Why?
|
| Osteoclasts | 1 | 1998 | 165 | 0.010 |
Why?
|
| Child | 2 | 1996 | 29154 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 4298 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 2001 | 652 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 1303 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 968 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 1998 | 253 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 378 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 925 | 0.010 |
Why?
|
| Cartilage | 1 | 1997 | 128 | 0.010 |
Why?
|
| Infant | 1 | 1992 | 13310 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1998 | 370 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1997 | 152 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 689 | 0.010 |
Why?
|
| United States | 1 | 2013 | 15433 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1997 | 292 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2403 | 0.010 |
Why?
|
| Nausea | 1 | 1997 | 525 | 0.010 |
Why?
|
| Arteries | 1 | 1997 | 274 | 0.010 |
Why?
|
| Pericarditis | 1 | 1996 | 61 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1995 | 100 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 1544 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2001 | 3005 | 0.010 |
Why?
|
| Uterus | 1 | 1998 | 678 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 500 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1997 | 1338 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 3443 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1998 | 4143 | 0.010 |
Why?
|
| Stem Cells | 1 | 1997 | 1213 | 0.010 |
Why?
|
| Mice | 2 | 1998 | 34495 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1997 | 6942 | 0.000 |
Why?
|
| Animals | 2 | 1998 | 59536 | 0.000 |
Why?
|